| Identification | Back Directory | [Name]
ATB 346 | [CAS]
1226895-20-0 | [Synonyms]
ABT-346
ATB 346
CS-1282
ATB346;ATB 346
ATB-346, >=98%
ATB 346,1226895-20-0
4-CARBAMOTHIOYLPHENYL 2-(6-METHOXYNAPHTHALEN-2-YL)PROPANOATE
2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 4-(aminothioxomethyl)phenyl ester
6-Methoxy-alpha-methyl-2-naphthaleneacetic acid 4-(aminothioxomethyl)phenyl ester
6-Methoxy-alpha-methyl-2-naphthaleneacetic acid 4-(aminothioxomethyl)phenyl ester ATB 346
ATB 346 6-Methoxy-alpha-methyl-2-naphthaleneacetic acid 4-(aminothioxomethyl)phenyl ester | [Molecular Formula]
C21H19NO3S | [MDL Number]
MFCD19443776 | [MOL File]
1226895-20-0.mol | [Molecular Weight]
365.45 |
| Chemical Properties | Back Directory | [Boiling point ]
561.4±60.0 °C(Predicted) | [density ]
1.261±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥18.27 mg/mL in DMSO | [form ]
solid | [pka]
12.37±0.29(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
ATB-346 is a non-steroidal anti-inflammatory drug (NSAID) that releases hydrogen sulfide (H2S) and a derivative of naproxen . It inhibits the proliferation of, and induces apoptosis in, A375 melanoma cells when used at a concentration of 100 μM. ATB-346 decreases prostaglandin E2 (PGE2) production in inflammatory exudates, reduces paw edema, and increases plasma levels of sulfide in a mouse model of zymosan-induced arthritis. It reduces the size of acetic acid-induced gastric ulcers in mice when administered at a dose of 60 μmol/kg. ATB-346 (30 μmol/kg) improves motor function in a mouse model of spinal cord injury. | [Uses]
Otenaproxesul (ATB-346), an orally active non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase-1 and 2 (COX-1 and 2). Otenaproxesul possesses antiinflammatory and antinociceptive activities[1][4]. | [in vivo]
Otenaproxesul exhibits anti-inflammatory properties similar to naproxen, but with substantially reduced gastrointestinal toxicity[1].
Otenaproxesul (orally, 43 μmol/kg) inhibits growth of melanoma tumors in vivo and reduce plasma levels of melanoma-associated chemokines[2].
Otenaproxesul (orally, 16 mg/kg) results in significant inhibition of bone defect and other histological characteristics (such as flatness of the gingival epithelium, chronic inflammatory cell infiltration and loss of connective tissue in the gingival papillae). Otenaproxesul inhibits the increase of gingival IL-1β and IL-6 secondary to periodontitis, but IL-10 is unaffected[3].
| Animal Model: | Male, Wistar rats (200-225 g)[1]. | | Dosage: | 30, 60, 120 and 2740 μmol/kg. | | Administration: | Orally once. | | Result: | Inhibited PGE2 levels.
Suppressed TXB2 synthesis.
|
| Animal Model: | Male, Wistar rats (200-225 g)[1]. | | Dosage: | 4 μmol/kg. | | Administration: | Orally twice daily, on days 7 to 21.
| | Result: | Significantly reduced paw oedema at days 14 and 21 (*P < 0.05 vs. the vehicle-treated group).
Caused markedly less gastric damage at all doses tested than naproxen.
|
| [IC 50]
COX-1; COX-2 | [References]
[1] wallace j l, caliendo g, santagada v, et al. markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (atb-346). british journal of pharmacology, 2010, 159(6): 1236-1246. |
|
|